SCHEMBL6315943

SCHEMBL6315943

NC(=O)c1c(-c2cccs2)noc1NC(=O)C(Cl)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.41
MEN1 O00255 6/20 0.41
ALDH1A1 P00352 7/20 0.39
MAPT P10636 5/20 0.39
GAA P10253 3/20 0.39
HSD17B10 Q99714 3/20 0.39
HTT P42858 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
RET P07949 1/20 0.39
PLK1 P53350 1/20 0.38
NPC1 O15118 5/20 0.38
RAB9A P51151 4/20 0.36
KDM4E B2RXH2 4/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 1/20 0.36
PAX8 Q06710 1/20 0.36
POLB P06746 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317514 0.83 KMT2A (0.45) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6314763 0.83 MEN1 (0.40) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6314638 0.80 ALDH1A1 (0.54) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6315246 0.80 KDM4E (0.53) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6315905 0.79 KDM4E (0.51) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6318389 0.78 ALDH1A1 (0.43) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6318058 0.76 KMT2A (0.54) KMT2AMEN1ALDH1A1MAPTHSD17B10
SCHEMBL6318622 0.76 MAPT (0.47) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6318172 0.76 NPC1 (0.50) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL6318380 0.76 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KMT2A 1089/4885MEN1 2789/4885ALDH1A1 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.